Literature DB >> 22967259

High one year mortality in adults with sickle cell disease and end-stage renal disease.

Ann C McClellan1, Jean-Christophe Luthi, Janet R Lynch, J Michael Soucie, Roshni Kulkarni, Antonio Guasch, Edwin D Huff, David Gilbertson, William M McClellan, Michael R DeBaun.   

Abstract

Adequate pre-dialysis care reduces mortality among end-stage renal disease (ESRD) patients. We tested the hypothesis that individuals with ESRD due to sickle cell disease (SCD-ESRD) receiving pre-ESRD care have lower mortality compared to individuals without pre-ESRD care. We examined the association between mortality and pre-ESRD care in incident SCD-ESRD patients who started haemodialysis between 1 June, 2005 and 31 May, 2009 using data provided by the Centers for Medicare and Medicaid Services (CMS). SCD-ESRD was reported for 410 (0·1%) of 442 017 patients. One year after starting dialysis, 108 (26·3%) patients with incident ESRD attributed to SCD died; the hazard ratio (HR) for mortality among patients with SCD-ESRD compared to those without SCD as the primary cause of renal failure was 2·80 (95% confidence interval [CI] 2·31-3·38). Patients with SCD-ESRD receiving pre-dialysis nephrology care had a lower death rate than those with SCD-ESRD who did not receive pre-dialysis nephrology care (HR = 0·67, 95% CI 0·45-0·99). The one-year mortality rate following an ESRD diagnosis was almost three times higher in individuals with SCD when compared to those without SCD but with ESRD and could be attenuated by pre-dialysis nephrology care.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22967259      PMCID: PMC4562224          DOI: 10.1111/bjh.12024

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  III. NKF-K/DOQI Clinical Practice Guidelines for Vascular Access: update 2000.

Authors: 
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

2.  IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.

Authors: 
Journal:  Am J Kidney Dis       Date:  2001-01       Impact factor: 8.860

3.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

4.  Vascular access and increased risk of death among hemodialysis patients.

Authors:  Stephen Pastan; J Michael Soucie; William M McClellan
Journal:  Kidney Int       Date:  2002-08       Impact factor: 10.612

5.  Population estimates of sickle cell disease in the U.S.

Authors:  Kathryn L Hassell
Journal:  Am J Prev Med       Date:  2010-04       Impact factor: 5.043

6.  United States Renal Data System 2008 Annual Data Report.

Authors:  Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa
Journal:  Am J Kidney Dis       Date:  2009-01       Impact factor: 8.860

7.  Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Authors:  Russell E Ware; Renee C Rees; Sharada A Sarnaik; Rathi V Iyer; Ofelia A Alvarez; James F Casella; Barry L Shulkin; Eglal Shalaby-Rana; C Frederic Strife; John H Miller; Peter A Lane; Winfred C Wang; Scott T Miller
Journal:  J Pediatr       Date:  2010-01       Impact factor: 4.406

8.  Treatment center and geographic variability in pre-ESRD care associate with increased mortality.

Authors:  William M McClellan; Haimanot Wasse; Ann C McClellan; Adam Kipp; Lance A Waller; Michael V Rocco
Journal:  J Am Soc Nephrol       Date:  2009-03-25       Impact factor: 10.121

9.  Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Brian D Bradbury; Rachel B Fissell; Justin M Albert; Mary S Anthony; Cathy W Critchlow; Ronald L Pisoni; Friedrich K Port; Brenda W Gillespie
Journal:  Clin J Am Soc Nephrol       Date:  2006-11-29       Impact factor: 8.237

10.  Revisiting normal (51)Cr-ethylenediaminetetraacetic acid clearance values in children.

Authors:  A Piepsz; M Tondeur; H Ham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

View more
  36 in total

1.  Changes in Conjunctival Hemodynamics Predict Albuminuria in Sickle Cell Nephropathy.

Authors:  Ali Kord Valeshabad; Justin Wanek; Santosh L Saraf; Bruce I Gaynes; Victor R Gordeuk; Robert E Molokie; Mahnaz Shahidi
Journal:  Am J Nephrol       Date:  2015-08-05       Impact factor: 3.754

Review 2.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

3.  Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.

Authors:  Malgorzata Kasztan; Brandon M Fox; Jeffrey D Lebensburger; Kelly A Hyndman; Joshua S Speed; Jennifer S Pollock; David M Pollock
Journal:  Blood Adv       Date:  2019-05-14

4.  Severe anemia early in life as a risk factor for sickle-cell kidney disease.

Authors:  Inmaculada Aban; Sujatha Baddam; Lee M Hilliard; Thomas H Howard; Daniel I Feig; Jeffrey D Lebensburger
Journal:  Blood       Date:  2016-12-05       Impact factor: 22.113

5.  Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT.

Authors:  Courtney D Fitzhugh; Matthew M Hsieh; Tiffani Taylor; Wynona Coles; Katherine Roskom; Delon Wilson; Elizabeth Wright; Neal Jeffries; Christopher J Gamper; Jonathan Powell; Leo Luznik; John F Tisdale
Journal:  Blood Adv       Date:  2017-04-19

6.  The morbidity and mortality of end stage renal disease in sickle cell disease.

Authors:  Maya Viner; Jifang Zhou; David Allison; Jin Han; Robert E Molokie; Shivi Jain; Michel Gowhari; Victor R Gordeuk; Gregory Calip; Santosh L Saraf
Journal:  Am J Hematol       Date:  2019-03-01       Impact factor: 10.047

7.  Prevalence of acute kidney injury during pediatric admissions for acute chest syndrome.

Authors:  Jeffrey D Lebensburger; Prasannalaxmi Palabindela; Thomas H Howard; Daniel I Feig; Inmaculada Aban; David J Askenazi
Journal:  Pediatr Nephrol       Date:  2016-03-24       Impact factor: 3.714

8.  Renal Failure in Sickle Cell Disease: Prevalence, Predictors of Disease, Mortality and Effect on Length of Hospital Stay.

Authors:  Sri L H Yeruva; Yonette Paul; Patricia Oneal; Mehdi Nouraie
Journal:  Hemoglobin       Date:  2016-09-18       Impact factor: 0.849

9.  End points for sickle cell disease clinical trials: renal and cardiopulmonary, cure, and low-resource settings.

Authors:  Ann T Farrell; Julie Panepinto; Ankit A Desai; Adetola A Kassim; Jeffrey Lebensburger; Mark C Walters; Daniel E Bauer; Rae M Blaylark; Donna M DiMichele; Mark T Gladwin; Nancy S Green; Kathryn Hassell; Gregory J Kato; Elizabeth S Klings; Donald B Kohn; Lakshmanan Krishnamurti; Jane Little; Julie Makani; Punam Malik; Patrick T McGann; Caterina Minniti; Claudia R Morris; Isaac Odame; Patricia Ann Oneal; Rosanna Setse; Poornima Sharma; Shalini Shenoy
Journal:  Blood Adv       Date:  2019-12-10

10.  Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Authors:  Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik
Journal:  Blood Adv       Date:  2020-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.